Allot Allows Telecom Providers to Leverage Their Networks for Increased Revenues; We view Allot`s Mobile Network Security operations as a growth engine for the company’s revenues in the coming years; we initiate coverage on Allot at a share price target of $12.0 Post author:jaimeuss_admin Post published:2 בOctober 2018 Post category:Research Continue ReadingAllot Allows Telecom Providers to Leverage Their Networks for Increased Revenues; We view Allot`s Mobile Network Security operations as a growth engine for the company’s revenues in the coming years; we initiate coverage on Allot at a share price target of $12.0
Vonetize. After delay, launch of operations in Russia expected by the end of 2018; the company needs additional sources of funding; acquisition by Desilu Studios is still awaiting completion; target price has been reduced to NIS 1.00. Post author:jaimeuss_admin Post published:2 בOctober 2018 Post category:Research Continue ReadingVonetize. After delay, launch of operations in Russia expected by the end of 2018; the company needs additional sources of funding; acquisition by Desilu Studios is still awaiting completion; target price has been reduced to NIS 1.00.
Kadimastem has raised NIS 15M which will fund clinical and pre-clinical development for cellular therapy; target price unchanged. Post author:jaimeuss_admin Post published:2 בOctober 2018 Post category:Research Continue ReadingKadimastem has raised NIS 15M which will fund clinical and pre-clinical development for cellular therapy; target price unchanged.
SAFE-T. NASDAQ IPO – $7.3M raised strengthens equity structure; significant growth in revenues and backlog offset by a substantially increased burn rate due to operational and technological expansion; valuation retained, however due to additional shares, target price decreased to NIS 3.85. Post author:jaimeuss_admin Post published:2 בOctober 2018 Post category:Research Continue ReadingSAFE-T. NASDAQ IPO – $7.3M raised strengthens equity structure; significant growth in revenues and backlog offset by a substantially increased burn rate due to operational and technological expansion; valuation retained, however due to additional shares, target price decreased to NIS 3.85.
RedHill announces top-line results from Phase III study of RHB-104 in Crohn’s Disease; cash balance improved with $25M (gross) raised at a discount; Top-line results for TALICIA® (RHB-105) – H. pylori infection expected by the end of 2018; target price reduced to NIS 2.23 Post author:jaimeuss_admin Post published:2 בOctober 2018 Post category:Research Continue ReadingRedHill announces top-line results from Phase III study of RHB-104 in Crohn’s Disease; cash balance improved with $25M (gross) raised at a discount; Top-line results for TALICIA® (RHB-105) – H. pylori infection expected by the end of 2018; target price reduced to NIS 2.23
Enlight Renewable Energy. Increase in revenue from electricity sales in H1-2018 due to full commercial operation in Ireland and in Croatia; Housing Cabinet approval for the Bereshit Project received; Acquisition of rights to a wind energy project in Spain; All other projects are progressing as scheduled; In light of the company meeting our expectations stock target price remains unchanged. Post author:jaimeuss_admin Post published:2 בOctober 2018 Post category:Research Continue ReadingEnlight Renewable Energy. Increase in revenue from electricity sales in H1-2018 due to full commercial operation in Ireland and in Croatia; Housing Cabinet approval for the Bereshit Project received; Acquisition of rights to a wind energy project in Spain; All other projects are progressing as scheduled; In light of the company meeting our expectations stock target price remains unchanged.
DNA. Entera is now trading under NASDAQ:ENTX; Entera has completed Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism; BeamMed posted impressive revenue growth, with a strategic focus on the US; target price increased by 50% to NIS 1.19. Post author:jaimeuss_admin Post published:2 בOctober 2018 Post category:Research Continue ReadingDNA. Entera is now trading under NASDAQ:ENTX; Entera has completed Part 1 of a Phase 2 PK/PD Study in Hypoparathyroidism; BeamMed posted impressive revenue growth, with a strategic focus on the US; target price increased by 50% to NIS 1.19.